User login
LAS VEGAS—An injection of a patient’s bone marrow stem cells during rotator cuff surgery significantly improved healing and tendon durability, according to a study presented at the 2015 Annual Meeting of the American Academy of Orthopaedic Surgeons (AAOS).
The French study, of which a portion appeared in the September 2014 issue of International Orthopaedics, included 90 patients who underwent rotator cuff surgery. Forty-five of the patients received injections of bone marrow concentrate (BMC) mesenchymal stem cells (MSCs) at the surgical site, and 45 had their rotator cuff repaired or reattached without MSCs. Researchers tried to make the 2 groups as equivalent as possible based on rotator cuff tear size, tendon rupture location, dominate shoulder, gender, and age.
Patient ultrasound images were obtained each month following surgery for 24 months. In addition, magnetic resonance imaging was obtained of patient shoulders at 3 and 6 months following surgery, and at 1 year, 2 years, and 10 years following surgery.
At 6 months, all 45 of the patients who received MSCs had healed rotator cuff tendons, compared to 30 (67%) of the patients who did not receive MSCs. The use of BMC also prevented further ruptures or retears. At 10 years after surgery, intact rotator cuffs were found in 39 (87%) of the MSC patients, but just 20 (44%) of the non-MSC patients.
In addition, “some retears or new tears occurred after 1 year,” said lead study author Philippe Hernigou, MD, an orthopedic surgeon at the University of Paris. “These retears were more frequently associated with the control group patients who were not treated with MSCs.
“While the risk of a retear after arthroscopic repair of the rotator cuff has been well documented, publications with long-term follow-up (more than 3 years) are relatively limited,” said Dr. Hernigou. “Many patients undergoing rotator cuff repair surgery show advanced degeneration of the tendons, which are thinner and atrophic, probably explaining why negative results are so often reported in the literature, with frequent post-operative complications, especially retear. Observations in the MSC treatment group support the potential that MSC treatment has both a short-term and long-term benefit in reducing the rate of tendon retear.”
LAS VEGAS—An injection of a patient’s bone marrow stem cells during rotator cuff surgery significantly improved healing and tendon durability, according to a study presented at the 2015 Annual Meeting of the American Academy of Orthopaedic Surgeons (AAOS).
The French study, of which a portion appeared in the September 2014 issue of International Orthopaedics, included 90 patients who underwent rotator cuff surgery. Forty-five of the patients received injections of bone marrow concentrate (BMC) mesenchymal stem cells (MSCs) at the surgical site, and 45 had their rotator cuff repaired or reattached without MSCs. Researchers tried to make the 2 groups as equivalent as possible based on rotator cuff tear size, tendon rupture location, dominate shoulder, gender, and age.
Patient ultrasound images were obtained each month following surgery for 24 months. In addition, magnetic resonance imaging was obtained of patient shoulders at 3 and 6 months following surgery, and at 1 year, 2 years, and 10 years following surgery.
At 6 months, all 45 of the patients who received MSCs had healed rotator cuff tendons, compared to 30 (67%) of the patients who did not receive MSCs. The use of BMC also prevented further ruptures or retears. At 10 years after surgery, intact rotator cuffs were found in 39 (87%) of the MSC patients, but just 20 (44%) of the non-MSC patients.
In addition, “some retears or new tears occurred after 1 year,” said lead study author Philippe Hernigou, MD, an orthopedic surgeon at the University of Paris. “These retears were more frequently associated with the control group patients who were not treated with MSCs.
“While the risk of a retear after arthroscopic repair of the rotator cuff has been well documented, publications with long-term follow-up (more than 3 years) are relatively limited,” said Dr. Hernigou. “Many patients undergoing rotator cuff repair surgery show advanced degeneration of the tendons, which are thinner and atrophic, probably explaining why negative results are so often reported in the literature, with frequent post-operative complications, especially retear. Observations in the MSC treatment group support the potential that MSC treatment has both a short-term and long-term benefit in reducing the rate of tendon retear.”
LAS VEGAS—An injection of a patient’s bone marrow stem cells during rotator cuff surgery significantly improved healing and tendon durability, according to a study presented at the 2015 Annual Meeting of the American Academy of Orthopaedic Surgeons (AAOS).
The French study, of which a portion appeared in the September 2014 issue of International Orthopaedics, included 90 patients who underwent rotator cuff surgery. Forty-five of the patients received injections of bone marrow concentrate (BMC) mesenchymal stem cells (MSCs) at the surgical site, and 45 had their rotator cuff repaired or reattached without MSCs. Researchers tried to make the 2 groups as equivalent as possible based on rotator cuff tear size, tendon rupture location, dominate shoulder, gender, and age.
Patient ultrasound images were obtained each month following surgery for 24 months. In addition, magnetic resonance imaging was obtained of patient shoulders at 3 and 6 months following surgery, and at 1 year, 2 years, and 10 years following surgery.
At 6 months, all 45 of the patients who received MSCs had healed rotator cuff tendons, compared to 30 (67%) of the patients who did not receive MSCs. The use of BMC also prevented further ruptures or retears. At 10 years after surgery, intact rotator cuffs were found in 39 (87%) of the MSC patients, but just 20 (44%) of the non-MSC patients.
In addition, “some retears or new tears occurred after 1 year,” said lead study author Philippe Hernigou, MD, an orthopedic surgeon at the University of Paris. “These retears were more frequently associated with the control group patients who were not treated with MSCs.
“While the risk of a retear after arthroscopic repair of the rotator cuff has been well documented, publications with long-term follow-up (more than 3 years) are relatively limited,” said Dr. Hernigou. “Many patients undergoing rotator cuff repair surgery show advanced degeneration of the tendons, which are thinner and atrophic, probably explaining why negative results are so often reported in the literature, with frequent post-operative complications, especially retear. Observations in the MSC treatment group support the potential that MSC treatment has both a short-term and long-term benefit in reducing the rate of tendon retear.”